News › Clinical Practice, Industry News, Patient Care

Allergan Receives FDA Approval for Juvéderm Voluma XC for Mid-face Injection via Cannula

September 11, 2019

Allergan plc has announced it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm Voluma XC, a hyaluronic acid gel dermal filler, with a TSK Steriglide cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm Voluma XC in the cheek area. The TSK Steriglide has a unique design compared to other cannulas available on the market and features a patented tip design with a near-tip delivery port for precise product placement.
Read more at PR Newswire >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Merz Aesthetics’ Radiesse Receives FDA Approval for Décolleté Wrinkles
    • New Book “Get Found, Get Booked” Reveals a Smarter, Ethical Approach to Marketing for Med Spas and Wellness Practices
    • Growth, Capital and Control: Navigating Private Equity in Aesthetics
    • Med Spas Under the Microscope – The View From The FDA
    • Revance and Teoxane Announce RHA Dynamic Volume is Now Available